Q3 2024 EPS Estimates for Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) Lowered by Analyst

Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) – Stock analysts at HC Wainwright decreased their Q3 2024 earnings per share estimates for shares of Cadrenal Therapeutics in a research note issued to investors on Thursday, August 8th. HC Wainwright analyst J. Pantginis now expects that the company will post earnings per share of ($0.16) for the quarter, down from their prior forecast of ($0.12). HC Wainwright currently has a “Buy” rating and a $3.00 target price on the stock. The consensus estimate for Cadrenal Therapeutics’ current full-year earnings is ($0.36) per share. HC Wainwright also issued estimates for Cadrenal Therapeutics’ Q4 2024 earnings at ($0.17) EPS, FY2024 earnings at ($0.58) EPS, FY2025 earnings at ($0.44) EPS, FY2026 earnings at ($0.46) EPS, FY2027 earnings at ($0.46) EPS and FY2028 earnings at ($0.24) EPS.

Cadrenal Therapeutics Trading Up 12.6 %

Shares of Cadrenal Therapeutics stock opened at $0.50 on Monday. The company has a fifty day moving average price of $0.46 and a 200 day moving average price of $0.58. The stock has a market cap of $7.92 million, a price-to-earnings ratio of -1.60 and a beta of 1.71. Cadrenal Therapeutics has a twelve month low of $0.36 and a twelve month high of $2.17.

Cadrenal Therapeutics Company Profile

Cadrenal Therapeutics, Inc operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome.